Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
ibandronic acid wh stungulyf, lausn 3 mg
williams & halls ehf - acidum ibandronicum mónónatríum - stungulyf, lausn - 3 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
pulmozyme lausn í eimgjafa 1 mg/ml
roche pharmaceuticals a/s - dornase alfa inn - lausn í eimgjafa - 1 mg/ml
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
remurel (brabio 20 mg/ml stungulyf, lausn í áfylltri sprautu) stungulyf, lausn í áfylltri sprautu 20 mg/ml
zentiva k.s.* - glatiramer acetat - stungulyf, lausn í áfylltri sprautu - 20 mg/ml
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
riastap stungulyfs-/innrennslisstofn, lausn 1 g
csl behring gmbh* - human fibrinogen - stungulyfs-/innrennslisstofn, lausn - 1 g
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
solu-medrol stungulyfsstofn og leysir, lausn 40 mg
pfizer aps - methylprednisolonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 40 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
tisseel lausnir fyrir vefjalím
baxter medical ab - human fibrinogen; human factor xiii; bovine aprotinin; human thrombin; calcii chloridum; thrombin; protein - lausnir fyrir vefjalím
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
tranexamsyre pfizer (cyklokapron stungulyf, lausn) stungulyf/innrennslislyf, lausn 100 mg/ml
pfizer aps - tranexamic acid - stungulyf/innrennslislyf, lausn - 100 mg/ml
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
ventoline lausn í eimgjafa 1 mg/ml
glaxosmithkline pharma a/s - salbutamolum súlfat - lausn í eimgjafa - 1 mg/ml
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
hydroxocobalamin g.l. pharma (hydroxocobalamin pharmexon 1 mg/ml stungulyf, lausn) stungulyf, lausn 1 mg/ml
g.l. pharma gmbh - hydroxocobalaminum acetat - stungulyf, lausn - 1 mg/ml
Evrópusambandið -
íslenska -
EMA (European Medicines Agency)
xevudy
glaxosmithkline trading services limited - sotrovimab - covid-19 virus infection - Ónæmiskerfið sera og mótefni, - xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (covid-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe covid-19.